Key Market Indicator:
F&G: 27
25.535,80 NASDAQ · 47.425,00 DOW · 6.822,95 S&P · 4.134,77 Gold · 64,21 BRENT

One Community. One Spirit. N#1 Broker.
all asset classes · all possibilities

Switch View
Hedge the Peak | Protect your Profits
© PR Newswire
10.11.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
Article
News Preview
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the company's first-in-cl...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US12674W1099
Cabaletta Bio Inc
CABA
LISTED
NASDAQ
Cabaletta Bio Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US86881A1007
Surgery Partners Inc
SGRY
LISTED
NASDAQ
Surgery Partners, Inc. Announces Third Quarter 2025 Results
Article
News Preview
BRENTWOOD, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the third quarter ended September 30, 2025....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
More Info
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
10.11.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Presents Additional Data from MAPLE-HCM at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and American Heart Association Scientific Sessions 2025
Article
News Preview
Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers ...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
10.11.2025
ISIN: SG9999014716
WAVE Life Sciences Ltd
WVE
LISTED
NASDAQ
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceeding levels that led to weight loss and prevention of rebound weight gain following cessation of GLP-1 in preclinical models ...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US0554771032
Bicara Therapeutics Inc.
BCAX
LISTED
NASDAQ
Bicara Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: DK0010272202
Genmab A/S
GMAB
LISTED
CPH
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
Article
News Preview
Media Release...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US03770N1019
Apogee Therapeutics Inc
APGE
LISTED
NASDAQ
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
Article
News Preview
Pipeline programs continue to advance, with four clinical data readouts anticipated in 2026; APG777 trial readout timelines accelerated, with Phase 1b in asthma and APEX 52-week Part A data in AD anticipated in Q1 2026, APEX 16-week Part B data in AD in Q2 2026, and APG279 Phase 1b head-to-head readout against DUPIXENT in AD in 2H 2026...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM STOCK NOTICE: DexCom, Inc. Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 26 Deadline
Article
News Preview
New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company's senior executives for securities fraud after significant stock drops resulting from the potential violations of th...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: KY61559X1045
MoonLake Immunotherapeutics
MLTX
LISTED
NASDAQ
MLTX STOCK NOTICE: MoonLake Immunotherapeutics Investors with Losses may have been Misled by the Company and are Urged to Contact BFA Law by December 15 Deadline
Article
News Preview
New York, New York--(Newsfile Corp. - November 10, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against MoonLake Immunotherapeutics (NASDAQ: MLTX) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in MoonLake, you are...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
AVTR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Avantor, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
Article
News Preview
SAN DIEGO, Nov. 10, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that the Avantor class action lawsuit – captioned Building Trades Pension Fund of Western Pennsylvania v. Avantor, Inc., No. 25-cv-06187 (E.D. Pa.) – seeks to represent purchasers or acquirers of Avantor, Inc. (NYSE: AVTR) com...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: NL0010696654
Uniqure NV
QURE
LISTED
NASDAQ
uniQure Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Article
News Preview
~ Announced pivotal topline data from Phase I/II study of AMT-130 in Huntington’s disease met its primary and key secondary endpoints, demonstrating statistically significant slowing of disease progression at 36 months and supportive trends across key clinical and biomarker endpoints ~...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© PR Newswire
10.11.2025
ISIN: US1255091092
Cigna Group (The)
CI
LISTED
NYSE
Headspace for Cigna Healthcare Enhances Everyday Mental Health Support Through Self-Guided, Science Backed Resources
Article
News Preview
With more than 1/3 American workers experiencing anxiety, Cigna Healthcare expands early engagement and preventive mental health support for millions of people Headspace for Cigna Healthcare offers unique features only available to Cig...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US00972D1054
Akebia Therapeutics Inc
AKBA
LISTED
NASDAQ
Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Article
News Preview
Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US28106W1036
Editas Medicine Inc
EDIT
LISTED
NASDAQ
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
Article
News Preview
In vivo preclinical proof-of-concept data presented at AHA and ESGCT demonstrating >90% LDL-C reduction in non-human primates supports EDIT-401’s potential as a best-in-class, one-time therapy...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: BMG762791017
Roivant Sciences Ltd
ROIV
LISTED
NASDAQ
Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Article
News Preview
BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided a business update....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US15713L1098
CervoMed Inc.
CRVO
LISTED
NASDAQ
CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
Article
News Preview
Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB)...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US87990A1060
Tenaya Therapeutics Inc
TNYA
LISTED
NASDAQ
Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
Article
News Preview
Presentation of MyPEAK-1 Data and the American Heart Association Scientific Sessions Showed Consistent, Deeper, and Durable Improvement in Measures of Hypertrophy for Cohort 1 Patients...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US81734D1046
Septerna, Inc.
SEPN
LISTED
NASDAQ
Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results
Article
News Preview
SEP-479 Selected as Next-Generation Oral PTH1R Agonist Development Candidate...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US68062P1066
Olema Pharmaceuticals, Inc.
OLMA
LISTED
NASDAQ
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results
Article
News Preview
Olema Oncology Reports Third Quarter 2025 Financial and Operating Results...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US9032141049
Cogent Biosciences, Inc.
COGT
LISTED
NASDAQ
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
Article
News Preview
16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p<0.0001)...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US67080M1036
Nurix Therapeutics Inc
NRIX
LISTED
NASDAQ
Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors
Article
News Preview
Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise Dr. Dansey, formerly of Pfizer and Seagen, strengthens the Board’s research, drug development and commercialization expertise...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: KYG596651029
MeiraGTx Holdings PLC
MGTX
LISTED
NASDAQ
MeiraGTx Enters into Strategic Collaboration with Eli Lilly and Company to Develop and Commercialize Genetic Medicines in Ophthalmology
Article
News Preview
LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced a broad strategic collaboration in the area of ophthalmology with Eli Lilly and Company (“Lilly”)....
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US03770N1019
Apogee Therapeutics Inc
APGE
LISTED
NASDAQ
Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody
Article
News Preview
Interim Phase 1 results for APG333 exceeded trial objectives, demonstrated a half-life of approximately 55 days, and suppressed key biomarkers for 6 months following a single dose, supporting potential 3- and 6- month dosing...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: US82835W1080
ARS Pharmaceuticals Inc
SBTX
LISTED
NASDAQ
ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)
Article
News Preview
$32.5 million in revenue, including $31.3 million in neffy U.S. net product revenue in third quarter of 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: FR0014000MR3
Eurofins Scientific SE
ERF
LISTED
EURONEXT
Eurofins Scientific SE: Director/PDMR Shareholding
Article
News Preview
Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit
Article
News Preview
NEW YORK, Nov. 10, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purch...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
10.11.2025
ISIN: CA50206C1005
LIR Life Sciences Corp.
SKNY
LISTED
CSE
Lir Life Sciences Corp. Formerly Blackbird Critical Metals Corp. Announces Closing of Acquisition of Lir Life Sciences Inc.
Article
News Preview
VANCOUVER, BC / ACCESS Newswire / November 10, 2025 / Lir Life Sciences Corp. (CSE:SKNY) (formerly Blackbird Critical Metals Corp.) ("Lir Life Sciences" or the "Company") is pleased to announce, further to its news release dated August 14, 2025, that it has completed the acquisition (the "Transaction") of all of the is...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)         
Article
News Preview
REYKJAVIK, ICELAND (November 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer AG (“Bayer”) a...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: LU2458332611
Alvotech SA
ALVO
LISTED
ICE
UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
Article
News Preview
REYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the outcome of expedited infringement proceedings before the UK High Court by Regeneron Pharmaceuticals Inc. (“Regeneron”) and Bayer...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: NL0015002CX3
Qiagen NV
QGEN
LISTED
NYSE
QIAGEN Unveils QIAsymphony Connect and Showcases New Precision Oncology Innovations at AMP 2025
Article
News Preview
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the debut of QIAsymphony Connect, the next generation of QIAGEN’s widely adopted automated nucleic acid purification platform, at the 2025 AMP (Association for Molecular Pathology) annual meeting from November 11-15 in Boston. The first public introduction of QIAsymphony Con...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: FR0010331421
Innate Pharma SA
IPH
LISTED
EURONEXT
Innate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCL
Article
News Preview
Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the confirmatory Phase 3 protocol for lacutamab in cutaneous T-cell lymphomas (CTCL), with no further comments, clearing the trial to proceed. The planned...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF
Article
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announces a research collaboration with EVerZom to expand its Acute-On-Chronic Lier Fail...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: FR0004163111
Genfit SA
GNFT
LISTED
EURONEXT
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
Article
News Preview
Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today presents promising new preclinical data in ACLF at The Liver Meeting® 2025 with nitazoxa...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.11.2025
ISIN: CH0012032048
Roche Holding AG
ROG
LISTED
SIX
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
Article
News Preview
Basel, 10 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the first Phase III (FENhance 2) of two pivotal, similarly-designed Phase III studies (FENhance 1 and 2) in patients with relapsing multiple sclerosis (RMS) met its primary endpoint. Fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, significan...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US2521311074
Dexcom Inc
DXCM
LISTED
NASDAQ
ROSEN, NATIONAL INVESTOR RIGHTS COUNSEL, Encourages DexCom, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - DXCM
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between July 26, 2024 and September 17, 2025, both dates inclusive (the "Class Period") of the important December 29, 2025 lead plaintiff deadline.SO WHAT: If you purchased...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LANTHEUS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.SO WHAT: If y...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH DEADLINE ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ROSEN, A TOP RANKED LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.SO WHAT: If you...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
ROSEN, A TOP RANKED LAW FIRM, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has alrea...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent and SanegeneBio Announce Phase 1 Clinical Data for IBI3016 Presented at American Heart Association (AHA) 2025 Annual Meeting
Article
News Preview
IBI3016 demonstrates sustained and potent AGT mRNA suppression with preliminary evidence of antihypertensive efficacy after single-dose subcutaneous administration. The clinical Phase 1 data of IBI3016 further support the potential for biannual subcutaneous dosing for the treatment of hypertensi...
Themefolio
Profiler
Peergroup
© PR Newswire
10.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
BAX Investors Have Opportunity to Lead Baxter International Inc. Securities Fraud Lawsuit
Article
News Preview
NEW YORK, Nov. 9, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (N...
Themefolio
Profiler
Peergroup
© BusinessWire
10.11.2025
ISIN: US92764N1028
Vir Biotechnology Inc
VIR
LISTED
NASDAQ
Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
Article
News Preview
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Week 48 endpoint analysis from the Company’s Phase 2 SOLSTICE trial for chronic hepatitis delta (CHD) demonstrated that participants receiving a monthly dose of the combination of tobevibart and elebsiran achieved robust and sustained rates of hepatitis delta virus (HDV) RNA target not det...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Adults with Heterozygous Familial Hypercholesterolemia (HeFH) in Phase 3 CORALreef HeFH Trial
Article
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef HeFH trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistic...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.11.2025
ISIN: AU000000AVH4
Avita Medical Inc.
AVH
LISTED
ASX
AVITA Medical to Host Investor Webinar Briefing
Article
News Preview
AVITA Medical to Host Investor Webinar Briefing...
Themefolio
Profiler
Peergroup
© BusinessWire
09.11.2025
ISIN: US28176E1082
Edwards Lifesciences Corp.
EW
LISTED
NYSE
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease
Article
News Preview
Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28 million people living with heart valve disease worldwide. In the U.S. alone, valve disease contributes to more than 60,000 deaths annually, many dri...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.11.2025
ISIN: US7504911022
RadNet Inc
RDNT
LISTED
NASDAQ
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
Article
News Preview
LOS ANGELES, Nov. 09, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services and a premier global developer of digital health solutions, today reported financial results for its third quarter of 2025....
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US4718712023
Jasper Therapeutics, Inc.
JSPR
LISTED
NASDAQ
JSPR DEADLINE NOTICE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action - JSPR
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US00857U1079
agilon health inc
AGL
LISTED
NYSE
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages agilon health, inc. Investors to Inquire About Securities Class Action Investigation - AGL
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of agilon health, inc. (NYSE: AGL) resulting from allegations that agilon health may have issued materially misleading business information to the inves...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US8753722037
Tandem Diabetes Care Inc
TNDM
LISTED
NASDAQ
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDM
Article
News Preview
New York, New York--(Newsfile Corp. - November 9, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. (NASDAQ: TNDM) resulting from allegations that Tandem Diabetes Care may have issued materially misleading business information...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US5165441032
Lantheus Holdings Inc
LNTH
LISTED
NASDAQ
LANTHEUS DEADLINE: ROSEN, A GLOBAL INVESTOR RIGHTS LAW FIRM, Encourages Lantheus Holdings, Inc. Investors to Secure Counsel Before Important November 10 Deadline in Securities Class Action - LNTH
Article
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lantheus Holdings, Inc. (NASDAQ: LNTH) between February 26, 2025 and August 5, 2025, both dates inclusive (the "Class Period"), of the important November 10, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US60855R1005
Molina Healthcare Inc
MOH
LISTED
NYSE
MOH IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Molina Healthcare, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MOH
Article
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline.SO WHAT: If you pur...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US0718131099
Baxter International, Inc.
BAX
LISTED
NYSE
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Baxter International Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BAX
Article
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Baxter International Inc. (NYSE: BAX) between February 23, 2022 and July 30, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.SO WHAT:...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US0021202025
Atyr Pharma, Inc.
ATYR
LISTED
NASDAQ
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATYR
Article
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of aTyr Pharma, Inc. (NASDAQ: ATYR) between January 16, 2025 and September 12, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.SO WHAT: I...
Themefolio
Profiler
Peergroup
© Newsfile
09.11.2025
ISIN: US05352A1007
Avantor Inc
AVTR
LISTED
NYSE
ROSEN, HIGHLY RANKED INVESTOR COUNSEL, Encourages Avantor, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AVTR
Article
News Preview
New York, New York--(Newsfile Corp. - November 8, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Avantor, Inc. (NYSE: AVTR) between March 5, 2024 and October 28, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US6402683063
Nektar Therapeutics
NKTR
LISTED
NASDAQ
New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
Article
News Preview
Statistically significant and clinically meaningful improvements in mean ACQ-5 scores were reported at week 16 versus placebo in patients who had atopic dermatitis and a history of asthma Extended dosing with rezpegaldesleukin q2w supports 24-week induction peri...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US92532F1003
Vertex Pharmaceuticals Inc
VRTX
LISTED
NASDAQ
Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week
Article
News Preview
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) from the ongoing RUBY-3 trial at the American Society of Nephrology (ASN) Kidney Week 2025 in Houston, Texas. Pove is an investigational recombinant fusion protein therapeutic an...
Themefolio
Profiler
Peergroup
© PR Newswire
08.11.2025
ISIN: US4577301090
Inspire Medical Systems Inc
INSP
LISTED
NYSE
INSP Investors Have Opportunity to Lead Inspire Medical Systems, Inc. Securities Fraud Lawsuit
Article
News Preview
NEW YORK, Nov. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2025
ISIN: US02043Q1076
Alnylam Pharmaceuticals Inc
ALNY
LISTED
NASDAQ
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Article
News Preview
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneu...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
Indices
DAX, DOW, S&P, FTSE...
Realtime Trading
With & without leverage
Currencies
EUR, USD, JPY, BRL, GBP ....
50 FX-Pairs
Top Conditions, Tied spreads, Mini/Micro
Commodities
Brent, WTI, Coffee, Wheat....
Long & Short
Crude oil, Agricultural & more
Metals
Gold, Silver, Palladium, Platinum
Hedging
Soft-,Heavy-, Precious Metals
Stocks & ETF
TSLA, NFLX, NVDA, MSFT, AAPL ....
Leveraged Equity Trading
USA, Europe, Asia
More information, click here

More sector specific news

Your Press Release is missing or you want share news over GICS11? Drop us a line.

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 Select Sector SPDRs
* * *
More Sector related Investment Ideas
XLB
XLE
XLU
XLY
XLF
XLP
XLV
XLK
XLC
XLI
XLRE
© 2025 WEBs Investments ETFs
About the newsfeed
#1
What types of information are provided on this portal - and what purpose does it serve?
The portal provides structured, stock market-relevant company information that is specifically assigned to a particular economic sector. The focus is on current announcements from official NewsWire sources, supplemented by company profiles, filter options by sector and sector-specific research aids. The aim is to offer an interested group of people a systematically structured research environment that improves their understanding of sector developments and corporate strategies.
#2
Why are companies categorized according to a certain system?
Financial markets consist of thousands of listed companies with very different business models. In order to create transparency and comparability, companies worldwide are assigned to standardized classifications. These classifications help investors to better analyze markets, identify sector-specific trends and make more targeted investment decisions.
#3
What classification standards exist for grouping companies?
There are various industry classifications that are used depending on the region or application. The best known include GICS (Global Industry Classification Standard), ICB (Industry Classification Benchmark), NAICS (North American Industry Classification System) and TRBC (Thomson Reuters Business Classification). Most institutional investors and ETFs worldwide use GICS or ICB as a benchmark.
#4
What classification standard is this financial information portal based on?
The portal uses the Global Industry Classification Standard (GICS), which was jointly developed by MSCI and S&P Dow Jones Indices. GICS is widely used in the institutional financial world and forms the basis for many global equity indices, ETFs and research systems.
#5
What exactly does GICS mean - and how is the system structured?
GICS stands for Global Industry Classification Standard. It is a hierarchical structure that divides listed companies worldwide into four levels: Sector, Industry Group, Industry Sector and Sub-Industry. In total, the system comprises 11 main sectors, over 60 industries and more than 150 sub-categories. It allows a consistent, internationally comparable analysis of economic activities.
#6
Why is GICS important in the financial world?
GICS offers a standardized language for investment decisions. It makes it possible to compare companies with similar business models - regardless of country, stock exchange or company size. Many investment funds, indices and research houses use GICS as a basis for portfolio construction, risk analysis or market screening. This means that it also makes sense for private investors to use this structure as a guide.
#7
Who decides which GICS sector a company is assigned to?
The allocation is made by the index providers MSCI and S&P Dow Jones on the basis of a company's main business segment. The decisive factor is the segment from which the company generates the majority of its sales or operating profit. Changes in the business model or strategic realignments can lead to a company being assigned to a different industry or even a different sector.
#8
What is meant by the GICS sector "Materials"?

The GICS "Materials" sector comprises companies that are active in the production, processing or refinement of raw materials. This includes industries such as chemicals, building materials, paper & forest products and the entire metallurgical and mining industry. The sector is highly cyclical and is particularly sensitive to economic fluctuations and changes in global demand.

#9
Which companies typically belong to the Materials sector?
Typical representatives are international groups from the areas of chemicals production (e.g. BASF), precious metal mining (e.g. Barrick Gold), building materials production (e.g. Heidelberg Materials) or industrial gases (e.g. Linde). The shares of these companies are often heavily dependent on commodity prices and play a central role in industrial value chains.
#10
Where does the company news on this page come from?
The news is based on verified and publicly available sources such as BusinessWire, GlobeNewswire, PR Newswire, EQS, Newsfile, ACCESSNewswire and other NewsWire services. These platforms are used by listed companies to publish mandatory ad hoc announcements, financial reports or strategic developments. All content is prepared in a structured manner and, if a corresponding categorization is possible, brought together in industry-specific clusters.
#11
How is the sector-specific mapping of messages carried out?
Categorization is based on structured metadata (e.g. ISIN, ticker, sector classification) and a combination of keyword analysis and GICS mapping. This ensures that all news is assigned to the correct sector and - if available - the correct sub-sector.
#12
Why is the materials sector particularly interesting for investors?
The Materials sector is closely linked to global industrial production and offers both cyclical growth opportunities and hedging opportunities against inflation and raw material shortages. In addition, many companies in this sector play a key role in future topics such as electromobility, the energy transition and sustainable building materials.
#13
What distinguishes this project from traditional financial information portals?
In contrast to generic portals, this project focuses exclusively and specifically on a particular sector. The advantage for interested investors: Sector-specific information, news, market movements and company profiles can be filtered and analyzed in a more targeted manner. This enables more in-depth research and greater relevance for thematic investment decisions.
#14
Are smaller companies also represented here or only large corporations?
The newsfeed takes into account both large caps and mid and small caps. As a clear mapping criterion is required in order to enable the most precise possible allocation to a cluster, the ISIN of the listed company is generally used for this purpose, provided that this can be made available or mapped via corresponding newsfeed parameters.
#15
How up-to-date are the displayed messages?
The content is updated regularly. The publication follows the publications of the information source, the NewsWire feeds of the underlying distributors. Incoming reports are automatically processed, classified and displayed on the page. Timestamps and source information ensure maximum transparency.
#16
Can I also filter the news by sub-sector?
Yes, this is a central feature of the site. Within a main sector, you can filter specifically for sub-sectors such as "Metals & Mining". For particularly popular industries or developments within a meta-sector, it is possible to deviate from standard clusters. Special categories with particular information value enable thematic analyses to be carried out even more precisely.
#17
Are there plans to process other metasectors in a similar way?
Yes, this financial information portal is part of an extensive project in which separate information portals are being created for all the main sectors. The aim is to provide investors with a systematic, sector-based research tool - regardless of index affiliation or provider perspective.
#18
Why do companies publish announcements via NewsWire services at all?
NewsWire services such as BusinessWire or PR Newswire fulfill a regulatory function: they enable companies to publish price-sensitive information publicly and without discrimination. In many countries, the use of such services is a prerequisite for fulfilling publication obligations under capital market law. They also enable companies to reach the media, analysts and investors in a targeted manner.
#19
Can private or inactive companies also appear in such notifications?
Generally not. The platform focuses exclusively on listed companies whose disclosures are based on regulatory requirements or corporate strategy measures. Although private or unlisted companies occasionally publish announcements, these are not systematically processed or classified here.
#20
What happens when a company changes its business model - does its sector classification also change?
Yes, as a rule - but not automatically. The responsible classification institutes (e.g. MSCI and S&P for GICS) regularly check the relevance and consistency of the classifications. If there is a significant change in a company's sales or profit profile, it may be reclassified to a different industry or even a different sector. This usually takes place after fixed review cycles or upon request.
#21
How is it ensured that a company is correctly categorized if it is active in several business areas?
The categorization is based on the dominant sales segment. If a company is active in several sectors but generates 70% of its turnover with chemical products, for example, it is assigned to the GICS sector "Materials" - even if it also has activities in the energy or transportation sector. In borderline cases, additional qualitative assessment criteria apply.
#22
Are there any legal risks in the further use of the displayed content?
The content comes from public sources, but is partially subject to copyright protection - particularly with regard to text structure and layout. The excerpts and links provided on this portal are made within the scope of permitted use (e.g. right to quote or editorial processing). However, commercial use by third parties is not permitted without the express permission of the original providers.
#23
Who can I contact if I have general questions or legal concerns?
A central contact point is available for general inquiries, information on company recordings, compliance issues or copyright-relevant aspects. In rare cases, for example in the case of erroneously published information or justified requests for deletion, a review and, if necessary, removal from the public feed can take place. Please only use the official contact option in the legal notice or at the bottom of the page.
#24
Is advertising or third-party content also displayed on the portal?
Yes, in defined areas the portal can display advertising content or product-specific information from third parties - for example on sector-related financial services, research offers or trading platforms. This content is clearly marked as advertising or partner information and is separate from the editorial or automatically processed company news.
#26
Can I give feedback on the platform or submit suggestions?
Absolutely - feedback is expressly welcome. The platform is an open information service that is continuously being developed. Comments on functionality, data quality, usability or thematic extensions help to optimize the service for the benefit of users. You can submit your suggestions informally via the contact page or special feedback forms.
#27
I am an information provider - can I cooperate with the portal?
Yes, the portal is open to content-related, technical or editorial cooperation, provided that this contributes to the quality, relevance or dissemination of the offering. If you offer content, interfaces or services that could be useful in the context of stock market-related information, we would be pleased to hear from you. The platform offers flexible integration options and a professional environment for quality-assured content.
#28
Can the platform technology also be used for other applications or partners?
Yes, the platform is based on a modular, scalable infrastructure that can be adapted to different information contexts and industry models. Technical components such as data aggregation, structuring logic, classification mechanisms and semantic filters can also be made available for external projects or individual applications on request. Please contact us for cooperation or license models.
#29
Can the underlying company data also be licensed or reused?
Structured access to selected master data of listed companies - such as GICS mapping, ISIN mapping, news feeds or metadata filters - is generally possible. The offer is aimed in particular at information service providers, research platforms or data-driven financial applications. Data can be provided via defined interfaces (e.g. API) or exportable formats, depending on the intended use and license framework.
#30
What forms of cooperation with external partners are conceivable?
Basically open. Possible forms of cooperation range from technical integrations and shared data models to content syndication or white label solutions. Partnerships with institutions that are looking for access to quality-assured data, dynamically structured news or sector-specific analyses - for example in the FinTech, media or research environment - are particularly interesting. We look forward to hearing from business development or product management departments.
#31
Why does this portal differ technically and conceptually from other information offerings?
Because no one from outside the industry is trying to understand the financial market here - but because the know-how comes from the heart of the financial world. The technical platform was developed by a team that combines in-depth market knowledge with innovative system design. The result: information architecture with real relevance, not shop window technology.
#32
What makes the technical solution particularly interesting for operators of their own financial portals?
In addition to high adaptability, the platform impresses with its modular structure and the consistent implementation of industry-specific logic - from GICS mapping to metadata filtering. For providers who operate their own information portals, sector-specific data structures, news feeds or visualizations can be quickly integrated on this basis - either as a white label, API module or embedded solution.
#33
Why can a collaboration go beyond traditional development services?
Because we don't just program, we think: The technological implementation is based on a deep understanding of market cycles, regulations, data formats and investor needs. Anyone who cooperates with this platform benefits from a sparring partner at eye level - both technically and professionally. This creates added value that goes far beyond pure IT expertise.
#34
Note on copyright and the processing of original content
The corporate news presented on this information portal is based on publicly accessible sources such as BusinessWire, GlobeNewswire, PR Newswire or comparable news services. The content is processed as part of an automated or editorially supported structuring process without changing, shortening or reinterpreting the content of the original information. This is so-called "as is" information, the form and content of which corresponds to the originally published announcement. The rights to the original texts remain unrestrictedly with the respective publishers or copyright holders. This portal merely assumes a structural categorization and allocation within the framework of a news-journalistic offer. Independent commercial reuse, systematic reproduction or other use of the content by third parties is only permitted within the framework of the statutory provisions or with the consent of the copyright holder.
About GICS Health
GICS Health is part of the GICS Eleven information portfolio, which focuses primarily on information from listed companies in the health sector. The sector classification serves as a guide to navigate quickly and conveniently through the latest industry-specific news. Individual peer group clusters complement the news offering.
About GICS Eleven

GICS Eleven (G11, GICS11) bundles topic-specific content and enables quick access to relevant information thanks to its gate function. The project is largely based on the Global Industry Classification Standard (GICS®), which was developed by MSCI and Standard & Poor's and enables a breakdown into sectors. GICS® consists of 11 sectors, 24 industry branches, 69 industries and 158 sub-industries.

GICS® is a registered trademark of MSCI Inc. and S&P Dow Jones Indices.

Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Tuesday, 11.11.2025, Calendar Week 46, 315th day of the year, 50 days remaining until EoY.